07:49 AM EDT, 08/21/2025 (MT Newswires) -- Aptorum Group ( APM ) and DiamiR Biosciences said Thursday that DiamiR has received a Clinical Laboratory Evaluation Program Test Approval for its APOE Genotyping test from the New York State Department of Health.

The company said the APOE test identifies genetic variants associated with risk for late-onset Alzheimer's disease and other neurological conditions.

The approval allows DiamiR to offer its APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, the company said.

DiamiR Biosciences and Aptorum Group ( APM ) agreed to an all-stock-merger in July, which is expected to close in Q4.

Aptorum Group ( APM ) shares climbed by more than 75% in premarket trading.